Business
4 min read
What The $15 Billion Menopause Market Overlooks
The booming menopause industry promises relief, but its economic focus obscures deeper inequities in women's health—and the complexities of aging itself.
The menopause market is projected to reach $15 billion by 2025, a figure that reflects both the scale of demand and the commercialization of a natural biological transition. Yet this economic surge obscures a more troubling reality: the industry’s growth is built on a narrow definition of menopause as a medical condition requiring intervention, rather than a multifaceted experience shaped by race, class, and geography. While hormone therapies, supplements, and high-end wellness retreats dominate the conversation, millions of women—particularly those in low-income communities and the Global South—remain invisible in both the marketplace and medical research. The promise of personalized solutions collides with structural inequities, leaving fundamental questions unanswered: Who gets access to care, and who is left to navigate symptoms alone?
The menopause industry’s rapid expansion is fueled by a perfect storm of demographic shifts and cultural change. As women over 50 become the fastest-growing segment of the global workforce, their purchasing power has attracted unprecedented investment. Pharmaceutical companies, tech startups, and wellness brands now compete to redefine menopause as a lucrative opportunity rather than an inevitable phase of life. Yet this framing risks reducing a complex biological and psychological experience to a series of transactions—one where solutions are marketed to those who can afford them, while the rest are left to improvise. The result is a market that thrives on visibility for some and neglects the systemic barriers that render others invisible.
The economic focus on menopause also reveals a troubling gap in medical research, where studies have historically prioritized conditions affecting men. Women’s health, particularly during midlife, has long been underfunded and misunderstood, with menopause often dismissed as an inevitable decline rather than a critical area for scientific inquiry. Even as awareness grows, clinical trials remain disproportionately white and affluent, failing to account for how race, genetics, and socioeconomic status influence symptoms and treatment efficacy. This lack of diversity in research perpetuates a one-size-fits-none approach, where the experiences of Black, Latina, and Indigenous women—who often report more severe symptoms—are sidelined in favor of a homogenized narrative that benefits only those who fit the mold.
Beyond the laboratory, cultural attitudes toward aging further distort the menopause market’s priorities. In many societies, menopause is still shrouded in stigma, treated as a private struggle rather than a shared human experience. This silence allows the industry to dictate the terms of the conversation, framing menopause as a problem to be solved rather than a transition to be navigated. The rise of direct-to-consumer brands pitching everything from cooling pajamas to CBD gummies capitalizes on this discomfort, offering quick fixes that often lack rigorous evidence. Meanwhile, women in cultures where menopause is normalized—such as Japan, where it is associated with wisdom and social status—report fewer symptoms, suggesting that the market’s medicalized approach may be more about profit than necessity.
The inequities in menopause care are not just a matter of access but of representation. The women shaping the industry—whether as investors, entrepreneurs, or influencers—tend to be affluent, white, and based in Western countries. Their experiences, while valid, do not reflect the global diversity of menopausal women, many of whom face compounding challenges like limited healthcare, gender discrimination, and climate-related health risks. For example, women in regions with extreme heat may experience exacerbated symptoms like hot flashes, yet their needs are rarely addressed in product development. The market’s narrow lens not only excludes these voices but also reinforces the idea that menopause is a luxury concern, rather than a universal one.
Even within wealthy nations, the menopause market’s focus on premium solutions obscures the reality for those who cannot afford them. Hormone replacement therapy, once a standard treatment, has become increasingly expensive, with insurance coverage varying wildly. Meanwhile, over-the-counter supplements and wellness products—often unregulated—promise relief without guarantees, leaving women to gamble on their own health. This pay-to-play dynamic mirrors broader trends in healthcare, where innovation is driven by profitability rather than need. As a result, the most vulnerable women—those without disposable income or reliable medical advice—are left to manage symptoms with whatever tools they can scavenge, from DIY cooling hacks to unverified herbal remedies.
The $15 billion menopause market may be growing, but its narrow focus on commercial solutions risks entrenching a two-tiered system of care. While some women gain access to cutting-edge treatments and supportive communities, others are left to navigate symptoms in isolation, their struggles invisible to both researchers and investors. The industry’s reliance on a homogenized narrative of menopause not only fails to address the needs of marginalized women but also reinforces the idea that their experiences are less valid. Until the market reckons with its own blind spots—prioritizing equity over expansion—the promise of menopause as an opportunity for empowerment will remain hollow for those who need it most.
The economic focus on menopause also reveals a troubling gap in medical research, where studies have historically prioritized conditions affecting men. Women’s health, particularly during midlife, has long been underfunded and misunderstood, with menopause often dismissed as an inevitable decline rather than a critical area for scientific inquiry. Even as awareness grows, clinical trials remain disproportionately white and affluent, failing to account for how race, genetics, and socioeconomic status influence symptoms and treatment efficacy. This lack of diversity in research perpetuates a one-size-fits-none approach, where the experiences of Black, Latina, and Indigenous women—who often report more severe symptoms—are sidelined in favor of a homogenized narrative that benefits only those who fit the mold.
Beyond the laboratory, cultural attitudes toward aging further distort the menopause market’s priorities. In many societies, menopause is still shrouded in stigma, treated as a private struggle rather than a shared human experience. This silence allows the industry to dictate the terms of the conversation, framing menopause as a problem to be solved rather than a transition to be navigated. The rise of direct-to-consumer brands pitching everything from cooling pajamas to CBD gummies capitalizes on this discomfort, offering quick fixes that often lack rigorous evidence. Meanwhile, women in cultures where menopause is normalized—such as Japan, where it is associated with wisdom and social status—report fewer symptoms, suggesting that the market’s medicalized approach may be more about profit than necessity.
The inequities in menopause care are not just a matter of access but of representation. The women shaping the industry—whether as investors, entrepreneurs, or influencers—tend to be affluent, white, and based in Western countries. Their experiences, while valid, do not reflect the global diversity of menopausal women, many of whom face compounding challenges like limited healthcare, gender discrimination, and climate-related health risks. For example, women in regions with extreme heat may experience exacerbated symptoms like hot flashes, yet their needs are rarely addressed in product development. The market’s narrow lens not only excludes these voices but also reinforces the idea that menopause is a luxury concern, rather than a universal one.
Even within wealthy nations, the menopause market’s focus on premium solutions obscures the reality for those who cannot afford them. Hormone replacement therapy, once a standard treatment, has become increasingly expensive, with insurance coverage varying wildly. Meanwhile, over-the-counter supplements and wellness products—often unregulated—promise relief without guarantees, leaving women to gamble on their own health. This pay-to-play dynamic mirrors broader trends in healthcare, where innovation is driven by profitability rather than need. As a result, the most vulnerable women—those without disposable income or reliable medical advice—are left to manage symptoms with whatever tools they can scavenge, from DIY cooling hacks to unverified herbal remedies.
The $15 billion menopause market may be growing, but its narrow focus on commercial solutions risks entrenching a two-tiered system of care. While some women gain access to cutting-edge treatments and supportive communities, others are left to navigate symptoms in isolation, their struggles invisible to both researchers and investors. The industry’s reliance on a homogenized narrative of menopause not only fails to address the needs of marginalized women but also reinforces the idea that their experiences are less valid. Until the market reckons with its own blind spots—prioritizing equity over expansion—the promise of menopause as an opportunity for empowerment will remain hollow for those who need it most.